MSC-based Platform

Mesenchymal stem cells (MSCs) are the most commonly used cell therapy platform. The pleiotropic properties of MSCs allow their utilization for both immunomodulation and regeneration in treatment of various diseases.

CytoMed’s umbilical cord-derived MSC platform

Umbilical cord (UC) is a promising source of MSCs. Comparing with other adult sources of MSCs such as bone marrow- and adipose tissue-derived MSCs, UC-derived MSCs (UC-MSCs) have their apparent advantages, such as non-invasive starting material collection, faster self-renewal and young cells with minimal background genetic mutation. UC-MSCs can be expanded and cryopreserved until administration and can be developed into an “off-the-shelf” and ready-to-use cell product.